Despite increasing concerns over protectionist policies in China, Morgan Stanley believes that market-based choices will trump government policies during the next decade, leading to success for multinational companies over the long term in the world's fastest-growing market
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.
The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.
